Table 2.
The correlation between activities of uMMP-9 dimer with different uMMPs examined in bladder cancer patients
|
uMMPs |
MMP-9 dimer (%) |
Total |
Measurement of agreement |
p-value |
|
|---|---|---|---|---|---|
| |
Negative |
Positive |
|
|
|
| (31) | (53) | (kappa test) | |||
| MMP-2 |
|
|
|
|
|
| Negative |
26 (83.9) |
4 (11.4) |
30 |
|
|
| Positive |
5 (16.1) |
31 (88.6) |
36 |
0.726 |
<0.001 |
| MMP-9 |
|
|
|
|
|
| Negative |
24 (77.4) |
1 (2.9) |
25 |
|
|
| Positive |
7 (22.6) |
34 (97.1) |
41 |
0.754 |
<0.001 |
| MMP-9/NGAL |
|
|
|
|
|
| Negative |
25 (80.6) |
1 (2.9) |
26 |
|
|
| Positive |
6 (19.4) |
34 (97.1) |
40 |
0.785 |
<0.001 |
| MMP-9/TIMP |
|
|
|
|
|
| Negative |
29(93.5) |
29 (82.9) |
58 |
|
|
| Positive |
2 (6.5) |
6 (17.1) |
8 |
0.102 |
>0.05 |
| ADAMTS-7 |
|
|
|
|
|
| Negative |
26 (83.9) |
23 (65.7) |
49 |
|
>0.05 |
| Positive | 5 (16.1) | 12 (34.3) | 17 | 0.176 | |